Tesla (TSLA) Stock Faces Overhang as Musk–Trump Rift Deepens
Ives considers the Trump-Musk relationship to be a 'soap opera' that has become a significant overhang on Tesla's stock.
'As we discussed, this BFF situation has now turned into a soap opera that remains an overhang on Tesla's stock, with investors fearing that the Trump Administration will be more hawkish and show scrutiny around Musk-related US government spending related to Tesla and SpaceX, and most importantly the autonomous future, with the regulatory environment key to the future of Robotaxis and Cybercabs. We would expect the stock to be weak to kick off trading this morning as the Street will show concern that the Trump and Musk once BFF relationship now backfires and turns into a junior high school friendship gone bad into an enemy. "
Tesla, Inc. (NASDAQ:TSLA) is an automotive and clean energy company that leverages advanced artificial intelligence in its autonomous driving technology and robotics initiatives.
While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 AI Stocks in the Spotlight and
Disclosure: None.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Tesla May sales fall in big European markets ahead of new Model Y deliveries
By Amir Orusov and Nick Carey (Reuters) -Tesla's sales dropped for the fifth straight month in Britain, Germany and Italy in May, underscoring the challenges the electric vehicle-maker faces over CEO Elon Musk's politics and its model line-up. Demand for the company's new version of the Model Y - Europe's best-selling car as recently as 2023 - will boost sales in June when UK deliveries start, a British company spokesperson said. Tesla sales have plunged in some European markets and in China, as customers have favoured Chinese EVs because of their competitive prices and in some cases in protest at Musk's political activities. In Norway, however, the new Model Y, which the automaker has already started delivering there, has boosted sales. Deliveries of the revamped EV start this month in a number of other European markets. In an email sent to some media outlets late on Tuesday, a spokesman for Tesla in Britain said the decline in May sales was because the automaker had sold its stock of old Model Y cars as it awaited the new version from its factory in Berlin. Tesla has been "comfortably taking orders from customers" for the new Model Y in Britain, "with an increase expected" for its June sales, the spokesman wrote. The revamped Model Y enhances Tesla's ageing model range as traditional automakers and Chinese rivals launch EVs at a rapid pace. Tesla sales in Germany fell by more than a third in May, the German road traffic agency KBA said on Wednesday, even though sales of fully-electric cars rose 44.9%. KBA said Tesla sold 1,210 cars in Germany in May, down 36.2% from a year earlier. Sales from Chinese rival BYD increased ninefold to 1,857 units in May. In the United Kingdom, Europe's biggest EV market, Tesla's sales fell more than 45% in May while industry-wide sales jumped 28%. According to data from research firm New AutoMotive, the company was knocked into fifth place for EV sales behind Volkswagen, BMW and Volkswagen brands Audi and Skoda. In Italy, Tesla sales fell 20% in May, while industry-wide EV sales rose 40.8%.
Yahoo
24 minutes ago
- Yahoo
Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen 2.7% and is up 13% over the last 12 months, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an ever-evolving landscape. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 24.99% 39.09% ★★★★★★ Mereo BioPharma Group 53.64% 66.60% ★★★★★★ Ardelyx 21.03% 60.42% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Legend Biotech 26.68% 57.96% ★★★★★★ AVITA Medical 27.42% 61.05% ★★★★★★ Alnylam Pharmaceuticals 23.69% 60.42% ★★★★★★ Alkami Technology 20.53% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of approximately $4.20 billion. Operations: ADMA focuses on developing and marketing plasma-derived biologics, primarily generating revenue from its Biomanufacturing segment, which accounts for $449.41 million, while its Plasma Collection Centers contribute $9.83 million. ADMA Biologics, having recently become profitable, exhibits a promising trajectory with its earnings expected to surge by 21.6% annually. This growth outpaces the broader US market's forecast of 14.7%. The firm's commitment to innovation is underscored by a recent FDA approval for a production process that boosts yields by 20%, significantly enhancing operational efficiency. Moreover, ADMA has initiated a robust share repurchase program valued at $500 million, reflecting confidence in its financial health and future prospects. These strategic moves, coupled with revenue projections rising to over $625 million by 2026, position ADMA well within the biotech sector's competitive landscape. Click here and access our complete health analysis report to understand the dynamics of ADMA Biologics. Evaluate ADMA Biologics' historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on providing therapies for autoimmune diseases with significant unmet needs and has a market cap of $1.08 billion. Operations: Aurinia Pharmaceuticals generates revenue primarily through the research, development, and commercialization of therapeutic drugs, amounting to $247.30 million. Aurinia Pharmaceuticals has recently demonstrated a robust growth trajectory, with revenue forecasted to grow at 12.2% annually, outpacing the US market's average of 8.8%. This growth is complemented by an impressive expected annual earnings increase of 25.8%, signaling strong operational efficiency and market confidence. The company's strategic focus on R&D is evident from its significant investment, which has facilitated innovative treatments in lupus nephritis—highlighted by recent successful clinical results that are poised to enhance patient outcomes and potentially alter therapeutic standards in the industry. Furthermore, Aurinia's proactive approach to capital management is underscored by its recent share repurchases totaling $108.28 million, reinforcing its commitment to shareholder value amidst expanding market presence. Navigate through the intricacies of Aurinia Pharmaceuticals with our comprehensive health report here. Learn about Aurinia Pharmaceuticals' historical performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADTRAN Holdings, Inc. is a company that offers networking and communications platforms, software, systems, and services across the United States, Germany, the United Kingdom, and internationally with a market capitalization of approximately $711.86 million. Operations: ADTRAN Holdings generates revenue primarily through its Network Solutions segment, contributing $759.91 million, and its Services & Support segment, which adds $184.38 million. ADTRAN Holdings is distinguishing itself in the high-growth tech landscape, particularly through its recent deployment of FSP 3000 open optical transport technology. This innovation not only enhances data center interconnect capabilities for Cegeka but also integrates advanced security features like ConnectGuard™ optical-layer encryption and real-time fiber monitoring, ensuring high-capacity and reliable data transport. Furthermore, ADTRAN's strategic focus on R&D is evidenced by its significant annual investment in this area, aligning with industry trends towards more secure and scalable network solutions. With a revenue growth rate of 10.8% per year outpacing the US market average of 8.8%, and an impressive forecasted earnings growth of 107.3% annually, ADTRAN is well-positioned to capitalize on increasing demands for sophisticated networking solutions in various sectors including telecom and defense. Click here to discover the nuances of ADTRAN Holdings with our detailed analytical health report. Gain insights into ADTRAN Holdings' past trends and performance with our Past report. Discover the full array of 226 US High Growth Tech and AI Stocks right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADMA AUPH and ADTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
5 Macro Trends Likely to Send Bitcoin and XRP Skyrocketing in 2026
Macroeconomic factors have big implications for Bitcoin and XRP. Five such factors are currently becoming tailwinds for these two coins. Most of these trends will take a couple of years to play out in full. 10 stocks we like better than Bitcoin › Water seeks its own level, and so does money. When cash becomes plentiful in the financial system, scarce digital assets such as Bitcoin (CRYPTO: BTC) and XRP (CRYPTO: XRP) often move sharply higher. Looking toward 2026, there are five macroeconomic forces that appear ready to remove several roadblocks that have held crypto back during the past two years. XRP and Bitcoin are likely to go higher as a result. Here's why each matters. Think of liquidity as the total pool of spendable cash in the global economy. When central banks add money to their respective national financial systems, usually by enlarging their balance sheets, investors have more capital to deploy, and riskier assets like major cryptocurrencies benefit first. And since mid-2024, the total combined assets of the U.S. Federal Reserve, the European Central Bank, and the Bank of Japan have ticked higher for multiple quarters in a row. During the last comparable upswing, from March 2020 to April 2021, Bitcoin leapt 500%, while XRP surged 483%. So if major central banks keep refilling the punch bowl, history suggests another party for crypto prices, assuming nothing spoils the fun. Interest rates set the cost of borrowing money from central banks. Lower borrowing costs make cash cheaper and thus push investors to seek higher-return alternatives to government bonds, including leading digital assets like Bitcoin and XRP. The Fed is now widely anticipated to trim its benchmark interest rate by mid-2026, which implies at least a couple of interest rate cuts in the very near future. In 2019, when the Fed cut rates by almost 1 percentage point, Bitcoin rose 120% in five months, and XRP climbed 17%. That exact performance probably won't be replicated this time around, assuming things proceed as expected. But it will still likely be bullish for these coins. The U.S. Dollar Index is down roughly 8% so far in 2025 as worries over trade tensions and federal deficits mount. A weaker dollar means that global investors need fewer units of their local currency to buy dollar-denominated Bitcoin or XRP, which could have the effect of juicing demand. In 2017, a similar dollar slide that lasted through the start of 2018 preceded a jump in Bitcoin's market cap by a multiple of 13.5, and pushed XRP to rise by a shocking multiple of 34.6. As long as tariffs remain a topic of conversation for the U.S. economy, there could be a tailwind in play here. Government bond yields represent the safest return for investors. The 10-year U.S. Treasury yield has fallen from 4.7% in January 2025 to near 4.3% today. When safe yields drop, the gap between bonds and non-yielding assets such as crypto narrows, making coins more appealing in comparison. After yields slid in late 2018 until shortly after the start of their rapid climb back up in October 2021, Bitcoin's price rose by 572%, and XRP's followed, climbing 84% in the tail end of the period. When people have more disposable income, they invest more, and when they have invested in safe assets sufficiently, they move on to investing in riskier ones like Bitcoin or XRP. Paychecks are stretching a bit further after accounting for inflation recently; average hourly earnings in the U.S. rose 1.4% from March 2024 to March 2025. During the economic stimulus of the 2020 to 2021 period, fresh cash on the sidelines helped power Bitcoin's rise. There's no similarly strong stimulus this time around, but that doesn't change the fact that investors with deeper pockets are more likely to devote some of their money to cryptocurrencies like Bitcoin or XRP. Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Alex Carchidi has positions in Bitcoin. The Motley Fool has positions in and recommends Bitcoin and XRP. The Motley Fool has a disclosure policy. 5 Macro Trends Likely to Send Bitcoin and XRP Skyrocketing in 2026 was originally published by The Motley Fool Sign in to access your portfolio